NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA

Código QR

NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA

Guardado en:

Detalles Bibliográficos
Autor principal:	Özlem Tüfekçi
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/df4c644cad594ee8a2879b033d603922
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

PONATINIB EXPERIENCE IN A PEDIATRIC CHRONIC MYELOID LEUKEMIA PATIENT
por: Serap Karaman, et al.
Publicado: (2021)

Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias
por: Thomas X
Publicado: (2012)

EXPERIENCE OF GLASDEGIB IN PATIENTS WITH ELDERLY ACUTE MYELOID LEUKEMIA
por: Nanişe Gizem FENER, et al.
Publicado: (2021)

CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
por: Volkan KÖSE, et al.
Publicado: (2021)

T-ACUTE MYELOID LEUKEMIA CASE THOUGHT TO BE ASSOCIATED WITH RADIOIODINE (I¹³¹) TREATMENT
por: Merih Reis Aras, et al.
Publicado: (2021)

RETROSPECTIVE EVALUATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING VENATOCLAX-BASED TREATMENT
por: EMINE DURAK, et al.
Publicado: (2021)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
por: Anagnostou T, et al.
Publicado: (2018)

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia
por: Hooriyeh Shapoorian, et al.
Publicado: (2021)

A CHALLENGE IN PEDIATRIC ACUTE LEUKEMIA TREATMENT: UNEXPECTED, PROLONGED CYTOPENIA. IS IT BE CALLLED ‘INCOMPLETE HLH’?
por: Ersin Toret, et al.
Publicado: (2021)

VENETOCLAX AZACITIDINE COMBINATION THERAPY IN FIRST-LINE TREATMENT OF ACUTE MYELOID LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE
por: Melda Cömert, et al.
Publicado: (2021)

SECONDARY CHRONIC MYELOID LEUKEMIA FOLLOWING RADIOACTIVE IODINE (I131)
por: Yousef Hailan, et al.
Publicado: (2021)

Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
por: Waclaw J, et al.
Publicado: (2015)

First-line therapy of chronic myeloid leukemia &ndash; focus on dasatinib
por: Amrein PC
Publicado: (2012)

ACUTE ABDOMEN AND ITS OUTCOMES IN CHILDREN WITH ACUTE LEUKEMIA
por: Huseyin Avnı Solgun, et al.
Publicado: (2021)

Therapeutic developments in acute lymphoblastic leukemia
por: MacKenzie A, et al.
Publicado: (2012)

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
por: Natalia Estrada, et al.
Publicado: (2021)

AVASCULAR NECROSIS IN CHRONIC MYELOID LEUKEMIA: A REVIEW OF PATHOPHYSIOLOGY, PATIENTS’ CHARACTERISTICS, AND CLINICAL OUTCOMES
por: Abdulrahman Al-Mashdali, et al.
Publicado: (2021)

THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
por: Mohammad Abu-Tineh, et al.
Publicado: (2021)

ACUTE MEGACARYOBLASTIC LEUKEMIA IN CHILDREN: DIAGNOSTICS AND MRD MONITORING
por: Aleksandra Palladina, et al.
Publicado: (2021)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Rory M. Shallis, et al.
Publicado: (2021)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014)

POST-TREATMENT NUTRITIONAL STATUS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Akbar Akbarov, et al.
Publicado: (2021)

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
por: Elif KILIC KONTE, et al.
Publicado: (2021)

BONE AS A SITE OF EXTRAMEDULLARY DISEASE IN ACUTE LYMPHOBLASTIC LEUKEMIA
por: Fatma Tuba YILDIRIM, et al.
Publicado: (2021)

CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
por: Elrazi Ali, et al.
Publicado: (2021)

BONE MARROW NECROSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE REPORT
por: Melike Nur Ünal, et al.
Publicado: (2021)

Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients
por: Rytting ME
Publicado: (2012)

Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
por: Thomas X
Publicado: (2014)

CENTRAL HYPOTHROIDISM DUE TO ACUTE LYMPHOBLASTIC LEUKEMIA WITH CENTRAL NERVOUS SYSTEM INFILTRATION
por: Dilek Kaçar, et al.
Publicado: (2021)

HAPLOIDENTICAL VERSUS UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LEUKEMIA
por: Arnon Nagler
Publicado: (2021)

UNUSUAL METABOLIC COMPLICATIONS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: HYPERCALCEMIA, HYPERAMONEMIA, LACTIC ASIDOSIS
por: Dilek Kaçar, et al.
Publicado: (2021)

JUVENILE MYELOMONOCYTIC LEUKEMIA SINGLE CENTER EXPERIENCE
por: Yunus Murat Akcabelen, et al.
Publicado: (2021)

BK-VIRUS ASSOCIATED HAEMORRHAGIC CYSTITIS CONCOMITANT WITH CHEMOTHERAPY IN AN ADOLESCENT GIRL WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Aslı Turgutoğlu Yılmaz, et al.
Publicado: (2021)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Giancarlo Fatobene, et al.
Publicado: (2021)

MYC as therapeutic target in leukemia and lymphoma
por: Cortiguera MG, et al.
Publicado: (2015)

THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
por: Veysel GOK, et al.
Publicado: (2021)

MRI FINDINGS OF BONE MARROW AT THE BEGINNING OF LEUKEMIA
por: Seda Şahin, et al.
Publicado: (2021)

The expanding role of bendamustine in chronic lymphocytic leukemia
por: Nair KS, et al.
Publicado: (2015)

IL-15 as a potential target in leukemia
por: Xiong Y, et al.
Publicado: (2015)

Targeting CD20 in chronic lymphocytic leukemia
por: Nahas MR, et al.
Publicado: (2015)